Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice

PURPOSE: For patients with type 2 diabetes (T2DM) who remain above their glycemic target on insulin therapy, a combination of insulin and a glucagon-like peptide 1 receptor agonist has been recommended. However, few studies have been conducted to determine the clinical efficacy and parameters affect...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jiwoo, Cho, Yun Kyung, Kim, Hwi Seung, Jung, Chang Hee, Park, Joong-Yeol, Lee, Woo Je
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938178/
https://www.ncbi.nlm.nih.gov/pubmed/31920354
http://dx.doi.org/10.2147/DMSO.S231272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938178/
https://www.ncbi.nlm.nih.gov/pubmed/31920354
http://dx.doi.org/10.2147/DMSO.S231272

Ejemplares similares